Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIS43LS for Malaria Prevention in Mali
NCT04329104Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CIS43LS in malaria, sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2021; status: completed.
02
Drugs
CIS43LS
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04329104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329104.